| __timestamp | Regeneron Pharmaceuticals, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 7751000 |
| Thursday, January 1, 2015 | 838526000 | 10251000 |
| Friday, January 1, 2016 | 1177697000 | 9575000 |
| Sunday, January 1, 2017 | 1320433000 | 10912000 |
| Monday, January 1, 2018 | 1556200000 | 11049000 |
| Tuesday, January 1, 2019 | 1834800000 | 11646000 |
| Wednesday, January 1, 2020 | 1346000000 | 13265000 |
| Friday, January 1, 2021 | 1824900000 | 25805000 |
| Saturday, January 1, 2022 | 2115900000 | 35182000 |
| Sunday, January 1, 2023 | 2631300000 | 94999000 |
| Monday, January 1, 2024 | 2954400000 |
Unlocking the unknown
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc., from 2014 to 2023.
Regeneron Pharmaceuticals has demonstrated a robust upward trajectory in SG&A expenses, with a staggering 420% increase over the decade. This growth reflects their strategic investments in expanding operations and enhancing market presence. Notably, their expenses peaked in 2023, marking a significant milestone in their financial journey.
Conversely, Viridian Therapeutics, while smaller in scale, has shown a remarkable 1,125% rise in SG&A expenses, indicating aggressive scaling efforts. Their expenses surged notably in 2023, underscoring a pivotal year of transformation.
This comparative insight into SG&A trends offers a window into the strategic priorities and growth ambitions of these biotech leaders.
SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Viridian Therapeutics, Inc.